Agentix Corp.

AGTX

US00848A1034

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:48:33 17/05/2024 pm IST			5-day change	1st Jan Change
0.0354 ^USD	+54.13%		+54.35%	+14.52%

14/02	Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

AGENTIX CORP. : Change in Directors or Principal Officers (form 8-K)

June 05, 2021 at 02:48 am IST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.

On June 4, 2021, Scott Stevens resigned as a director of Agentix Corp. (the "Company). There were no disagreements between Mr. Stevens and the Company that caused his resignation.

Latest news about Agentix Corp.

Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	20/11	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023	22/23/22	CI
Agentix Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	14/23/14	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	14/23/14	CI
Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Agentix Corp. Reports Earnings Results for the Seven Months Ended March 31, 2022	18/22/18	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	18/22/18	CI
Agentix Corp. Appoints Salman Hoda as Member of the Board of Directors	15/22/15	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	13/22/13	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended November 30, 2021	13/22/13	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	07/21/07	CI
Agentix Corp. completed the acquisition of Applied BioPharma LLC.	31/21/31	CI
Agentix Corp. entered into an Agreement and Plan of Merger to acquire Applied BioPharma LLC.	14/21/14	CI
Agentix Corp. Reports Earnings Results for the Third Quarter Ended May 31, 2021	10/21/10	CI
Agentix Corp. Announces Resignation of Scott Stevens Resigned as A Director	05/21/05	CI
Agentix Corp. Reports Earnings Results for the Second Quarter Ended February 28, 2021	30/21/30	CI
GSL Healthcare, Inc. completed the acquisition of Agentix Corp. in a reverse merger transaction.	01/20/01	CI
GSL Healthcare, Inc. entered into an agreement to acquire Agentix Corp. in a reverse merger transaction for CAD 0.84 million.	29/20/29	CI

Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Companyâs wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
AGENTIX CORP.	+14.52%	1.42M
CSL LIMITED	-2.00%	90.27B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.12B
BIOGEN INC.	-15.73%	31.75B
UCB	+64.13%	26.6B
BIOMARIN PHARMACEUTICAL INC.	-21.28%	14.41B
INCYTE CORPORATION	-8.50%	12.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.87B